UA93284C2 - Поліетиленгліколь-g-csf кон'югат - Google Patents

Поліетиленгліколь-g-csf кон'югат

Info

Publication number
UA93284C2
UA93284C2 UAA200904695A UAA200904695A UA93284C2 UA 93284 C2 UA93284 C2 UA 93284C2 UA A200904695 A UAA200904695 A UA A200904695A UA A200904695 A UAA200904695 A UA A200904695A UA 93284 C2 UA93284 C2 UA 93284C2
Authority
UA
Ukraine
Prior art keywords
peg
csp
conjugate
mol
branched
Prior art date
Application number
UAA200904695A
Other languages
English (en)
Russian (ru)
Inventor
Єонг-Ву Йо
Вун-Йонг Йоо
Хьюн-Кюю Джеон
Юн-Кюю Чоі
Хіе-Ін Янг
Вьонг-Мун Кім
Сунг-Хі Лі
Су-Хьюнг Канг
Му-Хі Йоо
Original Assignee
Донг-А Фарм. Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Донг-А Фарм. Ко., Лтд. filed Critical Донг-А Фарм. Ко., Лтд.
Publication of UA93284C2 publication Critical patent/UA93284C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/77—Polymers containing oxygen of oxiranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Даний винахід стосується кон'югата триланцюгового PEG-G-CSF загальної формули (1), де відношення зв'язування триланцюгового поліетиленгліколю (PEG) та G-CSF становить 1:1 (мол/мол), a PEG має середню молекулярну масу від 200 до 45,000 дальтон; фармацевтичної композиції, що його містить, та способу його одержання. EMBED ISISServer (1)
UAA200904695A 2006-11-17 2006-11-22 Поліетиленгліколь-g-csf кон'югат UA93284C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020060113721A KR101079993B1 (ko) 2006-11-17 2006-11-17 폴리에틸렌글리콜 과립구 콜로니 자극인자 접합체
PCT/KR2006/004908 WO2008060002A1 (en) 2006-11-17 2006-11-22 Polyethylene glycol-g-csf conjugate

Publications (1)

Publication Number Publication Date
UA93284C2 true UA93284C2 (uk) 2011-01-25

Family

ID=39401799

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200904695A UA93284C2 (uk) 2006-11-17 2006-11-22 Поліетиленгліколь-g-csf кон'югат

Country Status (13)

Country Link
US (1) US8329191B2 (uk)
EP (1) EP2081580B1 (uk)
JP (1) JP5363987B2 (uk)
KR (1) KR101079993B1 (uk)
CN (1) CN101616678B (uk)
AU (1) AU2006350790B2 (uk)
BR (1) BRPI0622128A2 (uk)
ES (1) ES2433253T3 (uk)
MX (1) MX2009005205A (uk)
PL (1) PL2081580T3 (uk)
RU (1) RU2423133C2 (uk)
UA (1) UA93284C2 (uk)
WO (1) WO2008060002A1 (uk)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2415800T3 (da) * 2009-03-31 2013-12-02 Nof Corp Hyperforgrenet polyoxyalkylenforbindelse og fremgangsmåde til deres fremstilling
WO2014110867A1 (zh) * 2013-01-17 2014-07-24 厦门赛诺邦格生物科技有限公司 一种单一官能化的支化聚乙二醇及其修饰的生物相关物质
US9319147B2 (en) 2014-06-30 2016-04-19 Alcatel Lucent Optical receiver for quadrature-phase-shift-keying and quadrature-duobinary signals
CN108368162B (zh) * 2016-04-15 2021-11-12 江苏恒瑞医药股份有限公司 一种重组人粒细胞刺激因子的复性及纯化方法
EP3634487A4 (en) * 2017-06-09 2021-03-24 The Regents Of The University Of Colorado, A Body Corporate, A Colorado Non-Profit GM-CSF MIMETICS AND PROCESSES FOR THE PRODUCTION AND USE OF THEM
KR102020995B1 (ko) * 2017-10-30 2019-09-16 한국코러스 주식회사 콜로니자극인자와 폴리올이 접합된 접합물을 고수율로 제조하는 방법
US10882954B2 (en) 2019-04-11 2021-01-05 Sunbio Inc. Tertiary alkoxy polyethylene glycol and derivatives thereof
KR102958185B1 (ko) * 2021-09-28 2026-04-30 한양대학교 산학협력단 암 치료용 글리시리진-분지형 폴리에틸렌글리콜 컨쥬게이트

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5951974A (en) * 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
TW517067B (en) * 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
HK1049673A1 (zh) 1999-01-29 2003-05-23 霍夫曼-拉罗奇有限公司 Gcsf缀合物
CN1321134C (zh) * 2000-11-23 2007-06-13 赵剑 一种生物活性蛋白质的非均一制品及其制备方法
CN1176137C (zh) * 2002-01-15 2004-11-17 泛亚生物技术有限公司 多臂树杈型功能化聚乙二醇制备方法及它在药物中的应用
US7144978B2 (en) * 2002-01-15 2006-12-05 Pan Asia Bio Co., Ltd. Multidrop tree branching functional polyethylene glycol, methods of preparing and using same
EP1490402A4 (en) 2002-03-20 2007-05-02 Biopolymed Inc PREPARATION OF CYSTEINREST STOCHIOMETRIC WITH BIOKOMPATIBLE POLYMER CONJUGATED G-CSF
JP4412461B2 (ja) * 2002-11-20 2010-02-10 日油株式会社 修飾された生体関連物質、その製造方法および中間体
KR20040083268A (ko) 2003-03-21 2004-10-01 한미약품 주식회사 안정성이 증가된 인간 과립구 콜로니 자극인자 융합체 및이의 제조방법
KR100507796B1 (ko) 2003-04-03 2005-08-17 한미약품 주식회사 생체내 반감기가 증가된 ｐｅｇ-생리활성 폴리펩티드 동종이량체 결합체 및 이의 제조방법
WO2005055946A2 (en) * 2003-12-03 2005-06-23 Neose Technologies, Inc. Glycopegylated granulocyte colony stimulating factor
EP1586334A1 (en) 2004-04-15 2005-10-19 TRASTEC scpa G-CSF conjugates with peg
JP2008511610A (ja) * 2004-08-31 2008-04-17 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー グリセロール分岐のポリエチレングリコール−ヒト成長ホルモン結合体、それらの製造方法及び使用方法

Also Published As

Publication number Publication date
US20100105616A1 (en) 2010-04-29
CN101616678B (zh) 2012-10-03
JP5363987B2 (ja) 2013-12-11
RU2423133C2 (ru) 2011-07-10
KR101079993B1 (ko) 2011-11-04
PL2081580T3 (pl) 2014-01-31
US8329191B2 (en) 2012-12-11
WO2008060002A1 (en) 2008-05-22
EP2081580B1 (en) 2013-08-14
EP2081580A4 (en) 2011-08-10
JP2010510204A (ja) 2010-04-02
CN101616678A (zh) 2009-12-30
AU2006350790B2 (en) 2010-04-29
KR20080044639A (ko) 2008-05-21
EP2081580A1 (en) 2009-07-29
BRPI0622128A2 (pt) 2011-12-27
AU2006350790A1 (en) 2008-05-22
MX2009005205A (es) 2009-05-28
ES2433253T3 (es) 2013-12-10
HK1138799A1 (en) 2010-09-03
RU2009122976A (ru) 2010-12-27

Similar Documents

Publication Publication Date Title
MXPA05003394A (es) Conjugados de polimero con antigenicidad disminuida, metodos de preparacion y usos de estos.
MX2012000369A (es) Forma de dosificacion resistente a la manipulacion para opioides sensibles a la oxidacion.
EP2261236A3 (en) Composition for proteasome inhibition
WO2006005058A3 (en) Polymer-factor ix moiety conjugates
MX2008001706A (es) Conjugados de una porcion g-csf y un polimero.
NZ597912A (en) Pegylated l-asparaginase
MY148680A (en) Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
WO2008024435A3 (en) Dendritic molecular intracellular transporters and methods of making and using same
PL1758553T3 (pl) Kompozycje farmaceutyczne zawierające glikol polietylenowy o masie cząsteczkowej niższej niż 600 Daltonów
MXPA03008886A (es) Composiciones de baja respuesta glicemica.
EP2679244A3 (en) Formulations which stabilize and inhibit precipitation of immunogenic compositions
WO2008015249A3 (en) Cosmetic or pharmaceutical composition containing hyaluronic acid
EP2279758A3 (en) Conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates
EA201390600A1 (ru) Терапевтические наночастицы с сополимерами с большим молекулярным весом
MX347056B (es) Composiciones farmaceuticas.
EP3895699A3 (en) Pharmaceutical compositions comprising iron oxy-hydroxide
WO2008121348A3 (en) Peripheral opioid receptor antagonists and uses thereof
ATE246202T1 (de) Gcsf konjugate
WO2010138544A3 (en) Oral care formulations that enhance amount of soluble zinc
EP1598341A8 (en) DPP-IV inhibitors
WO2004113297A3 (en) Aza-ring derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
EP1604980A8 (en) DPP-IV inhibitors
WO2008088624A3 (en) Hydroxyl-terminated or carboxylic acid- terminated reactive monomer compositions, their preparation and their use
MX2009005205A (es) Conjugado de polietilenglicol-g-csf.
WO2012059725A8 (en) Peg or peg block copolymers for treating colorectal cancer